Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• The transcription factor EGR4 is implicated in small cell lung cancer proliferation.
• Heat Shock Factor-1 (HSF1) is a known regulator of cellular stress responses.

Purpose of the Study:

• To identify and characterize a novel splice variant of EGR4.
• To investigate the role of this variant in breast cancer, particularly HER2-amplified types.
• To explore the regulatory mechanisms and potential biomarker utility of the novel variant.

Main Methods:

• Identification of a novel EGR4 splice variant (EGR4-S) using molecular techniques.
• Analysis of EGR4-S expression in breast cancer cell lines with varying EGFR, HER2, and H-Ras expression.
• Assessment of EGR4-S regulation by HER pathway inhibitors, chemical stressors, and HSF1.
• Protein and mRNA analysis in HER2+ human breast tumors and patient-matched normal tissue.
• Functional studies involving EGR4-S knockdown in SKBR3 cells.

Main Results:

• A novel, shortened EGR4 splice variant (EGR4-S) was identified, regulated by HSF1.
• EGR4-S is upregulated in breast cell lines with high EGFR, HER2, and H-Ras expression and inhibited by HER pathway inhibitors.
• EGR4-S is preferentially expressed in HER2+ tumor tissue compared to normal tissue.
• Knockdown of EGR4-S reduced cell growth in HER2-amplified breast cancer cells.
• Suppression of EGR4-S by stressors or HSF1 overexpression led to reduced cell growth but increased metastatic potential.

Conclusions:

• EGR4-S is a novel splice variant that supports the growth of HER2+ breast tumors.
• EGR4-S is a potential biomarker for HER2 pathway activation in human tumors.
• HSF1 regulates EGR4-S expression, linking cellular stress to tumor growth and metastatic potential.